Shares of Aipeng Medical and Innovation Medical hit their daily upper limits, while Beiyikang's stock price soared 30% to close at its daily limit, signaling a robust rally in BCI stocks. BrainCo, a Chinese company listed in the US, witnessed a phenomenal 283% surge, prompting a broad-based upswing in related stocks in both Hong Kong and A-shares. BrainCo announced that its neuromodulation chip had secured FDA approval, a move that, despite initial skepticism, garnered significant market attention. Across both A-shares and Hong Kong stocks, several companies have intensified their investments in the BCI sector, leveraging policy support and technological advancements to expedite the industry's commercialization process. Forecasts indicate that the global market for BCI medical applications will reach a size of $40 billion to $145 billion by 2030-2040, underscoring its immense potential for growth.